专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5525607A Xanthine compounds 失效
标题翻译：黄嘌呤化合物
公开(公告)号：US5525607A
公开(公告)日：1996-06-11
申请号：US63684
申请日：1993-05-20
申请人： Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka , Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka
发明人： Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka , Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka
IPC分类号： C07D473/06 , C07D473/08 , C07D473/20 , C07D473/22 , A61K31/52 , C07D473/00
CPC分类号： C07D473/06 , C07D473/08 , C07D473/20 , C07D473/22
摘要： Novel xanthine compounds represented by the following formula: ##STR1## wherein each of R.sup.1, R.sup.2 and R.sup.3 independently represents hydrogen or lower alkyl;each of X.sup.1 and X.sup.2 independently represents oxygen or sulfur; and Q represents: ##STR2## The compounds are useful as a diuretic, a renal-protecting agent and bronchodilator.
摘要翻译：由下式表示的新型黄嘌呤化合物：其中R 1，R 2和R 3各自独立地表示氢或低级烷基; X1和X2各自独立地表示氧或硫; Q表示：该化合物可用作利尿剂，肾保护剂和支气管扩张剂。

2. 发明授权

US07601656B2 Leather-like sheet and process for producing thereof 失效
标题翻译：皮革状片材及其制造方法
公开(公告)号：US07601656B2
公开(公告)日：2009-10-13
申请号：US10588018
申请日：2005-02-10
申请人： Tomoyuki Horiguchi , Katsuhiko Mochizuki , Akira Karasawa
发明人： Tomoyuki Horiguchi , Katsuhiko Mochizuki , Akira Karasawa
IPC分类号： B32B5/26 , B32B5/06
CPC分类号： B32B5/26 , B32B3/30 , B32B5/022 , B32B5/024 , B32B5/026 , B32B5/04 , B32B5/06 , B32B5/08 , B32B2250/20 , B32B2262/0276 , B32B2262/0284 , B32B2307/51 , B32B2307/538 , B32B2307/554 , B32B2307/734 , B32B2307/736 , B32B2437/00 , B32B2601/00 , D01F8/14 , D02G3/045 , D04H3/16 , D06C29/00 , D06N3/0004 , D06N3/0013 , D10B2401/041 , Y10S428/904 , Y10T428/2395 , Y10T442/3146 , Y10T442/3154 , Y10T442/3163 , Y10T442/3707 , Y10T442/3724 , Y10T442/3772 , Y10T442/378 , Y10T442/444 , Y10T442/494
摘要： A leather-like sheet excellent in stretchability which is obtained by integrating by entanglement of a woven or knitted fabric and an ultrafine fiber of 0.0001 to 0.5 dtex, wherein at least one face of the leather-like sheet is substantially composed of said ultrafine fibers, and said woven or knitted fabric consists of a conjugate fiber in which two or more kinds of polyester-based polymers, at least one of which consists essentially of polytrimethylene terephthalate, are stuck along the fiber length direction side-by-side, or a conjugate fiber in which two or more kinds of polyester-based polymers, at least one of which consists essentially of polytrimethylene terephthalate, forms an eccentric sheath-core type conjugate structure, and the fiber constituting the woven or knitted fabric has a twist coefficient of 20000 or below.
摘要翻译：通过织造或针织物的缠结与0.0001〜0.5分特的超细纤维相结合而获得的拉伸性优异的皮革状片材，其中皮革状片材的至少一面基本上由所述超细纤维构成，所述机织针织物由共轭纤维组成，其中两种或多种聚酯基聚合物（其中至少一种基本上由聚对苯二甲酸丙二醇酯组成）沿着纤维长度方向并排粘合，或共轭物纤维，其中至少一种基本上由聚对苯二甲酸丙二醇酯组成的聚酯基聚合物形成偏心皮芯型共轭结构，构成机织或针织物的纤维的捻系数为20000或下面。

3. 发明授权

US07354949B2 Therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia 失效
公开(公告)号：US07354949B2
公开(公告)日：2008-04-08
申请号：US10472148
申请日：2002-03-29
申请人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa
发明人： Tsuyoshi Yamagata , Kaoru Atsuki , Tetsuji Ohno , Shiro Shirakura , Akira Karasawa
IPC分类号： A61K31/38 , A61K31/44 , A61K31/42
CPC分类号： C07D495/04 , A61K31/55
摘要： The present invention provides a therapeutic agent for bladder irritative symptoms associated with benign prostatic hyperplasia comprising, as an active ingredient, a tricyclic compound represented by formula (I): [wherein R1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy or halogen; X1-X2-X3 represents CR5═CR6—CR7═CR8, N(O)m═CR6—CR7═CR8, CR5═CR6—N(O)m═CR8, CR5═CR6—CR7═N(O)m, CR5═CR6—O, CR5═CR6—S, O—CR7═CR8, S—CR7═CR8 or O—CR7═N; Y represents 13 CH2S—, —CH2SO—, —CH2SO2—, —CH2O—, —CH═CH—, —(CH2)p—, —SCH2—, —SOCH2—, —SO2CH2— or —OCH2—; and R2 represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy, amino, mono(substituted or unsubstituted lower alkyl)-substituted amino, di(substituted or unsubstituted lower alkyl)-substituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkylamino, substituted or unsubstituted arylamino or a substituted or unsubstituted heteroalicyclic group] or a pharmaceutically acceptable salt thereof.

4. 发明授权

US06211227B1 Tricyclic compounds 失效
标题翻译：三环化合物
公开(公告)号：US06211227B1
公开(公告)日：2001-04-03
申请号：US09417626
申请日：1999-10-14
申请人： Makoto Yoshida , Takashi Seishi , Shigeru Aono , Tsuyoshi Yamagata , Kaoru Atsuki , Toshiaki Kumazawa , Haruki Takai , Koji Suzuki , Akira Karasawa
发明人： Makoto Yoshida , Takashi Seishi , Shigeru Aono , Tsuyoshi Yamagata , Kaoru Atsuki , Toshiaki Kumazawa , Haruki Takai , Koji Suzuki , Akira Karasawa
IPC分类号： A61K3138
CPC分类号： C07D495/04 , C07D313/12 , C07D337/12
摘要： The present invention provides tricyclic compounds which are useful for the treatment of pollakiuria and urinary incontinence and which are represented by general formula (I): (wherein R1 represents hydrogen, substituted or unsubstituted lower alkyl, etc.; X1—X2—X3 represents CR5═CR6—CR7═CR8 (wherein R5, R6, R7 and R8, which may be the same or different, each represents hydrogen, substituted or unsubstituted lower alkyl, hydroxy, substituted or unsubstituted lower alkoxy, etc.), N(O)m═CR5—CR6═CR7 (wherein R5, R6 and R7 have the same significances as defined above, and m represents 0 or 1), S—CR7═CR8 (wherein R7 and R8 have the same significances as defined above), etc.; and when R2 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, a substituted or unsubstituted N-substituted heterocyclic group, (wherein n is 0 or 1; R3 and R4, which may be the same or different, each represents hydrogen, substituted or unsubstituted lower alkyl, trifluoromethyl, etc., or R3 and R4 may be combined together to form cyclic alkyl; and Q represents hydroxy, halogen, etc.), etc., Y represents —CH2SO2—, —SCH2—, —SOCH2—, —SO2CH2—, etc.) and pharmaceutically acceptable salts thereof.
摘要翻译：本发明提供可用于治疗尿频和尿失禁的三环化合物，其由通式（I）表示：其中R 1表示氢，取代或未取代的低级烷基等; X 1 -X 2 -X 3表示CR 5 = CR6-CR7 = CR8（其中R5，R6，R7和R8可以相同或不同，各自表示氢，取代或未取代的低级烷基，羟基，取代或未取代的低级烷氧基等），N（O）m = CR5-CR6 = CR7（其中R5，R6和R7具有与上述相同的含义，m表示0或1），S-CR 7 = CR 8（其中R 7和R 8具有与上述相同的含义）等 ;当R 2表示氢时，取代或未取代的低级烷基，取代或未取代的低级烷氧基，取代或未取代的N-取代的杂环基，（其中n为0或1; R 3和R 4各自可相同或不同）代表氢，取代或未取代的低级烷基，三氟甲基脲基甲基等，或者R 3和R 4可以组合在一起形成环烷基; 和Q表示羟基，卤素等）等，Y表示-CH 2 SO 2 - ， - CH 2 - ， - SOCH 2 - ， - SO 2 CH 2 - 等）及其药学上可接受的盐。

5. 发明授权

US5648353A Quinazolines and phthalazines having adenosine uptake inhibitor activity 失效
标题翻译：喹唑啉和具有腺苷摄取抑制剂活性的酞嗪酮
公开(公告)号：US5648353A
公开(公告)日：1997-07-15
申请号：US446235
申请日：1995-05-22
申请人： Shigeki Fujiwara , Daisuke Machii , Haruki Takai , Hiromi Nonaka , Hiroshi Kase , Kozo Yao , Michiyo Kawakage , Hideaki Kusaka , Akira Karasawa
发明人： Shigeki Fujiwara , Daisuke Machii , Haruki Takai , Hiromi Nonaka , Hiroshi Kase , Kozo Yao , Michiyo Kawakage , Hideaki Kusaka , Akira Karasawa
IPC分类号： C07D401/14 , C07D491/04 , C07D401/04 , A61K31/445 , A61K31/50 , A61K31/505
CPC分类号： C07D401/14 , C07D491/04
摘要： The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, alkenyl, or substituted or unsubstituted aralkyl; R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently represent hydrogen, halogen, amino, mono- or di(lower alkyl)amino, lower alkanoylamino, nitro, cyano, substituted or unsubstituted lower alkyl, hydroxy, lower alkoxy, lower alkylthio, carboxy, lower alkoxycarbonyl, lower alkanoyl, aralkyloxy, or lower alkanoyloxy; R.sup.6, R.sup.7, R.sup.8, and R.sup.9 independently represent hydrogen, hydroxy, substituted or unsubstituted lower alkoxy, or aralkyloxy, or any adjoining two of them are combined to form methylenedioxy; R.sup.10 represents hydrogen or lower alkyl; and Y and Z independently represent N or C--R.sup.11 (wherein R.sup.11 represents hydrogen, substituted or unsubstituted lower alkyl, or halogen),or a pharmaceutically acceptable salt thereof as an active ingredient.
摘要翻译：本发明涉及腺苷摄取抑制剂和用于心肌保护或预防或治疗炎性水肿的药剂，其包含由式（I）表示的1,2,3,4-四氢-2,4-二氧代喹唑啉衍生物：（I）其中R 1表示氢，取代或未取代的低级烷基，烯基或取代或未取代的芳烷基; R2，R3，R4和R5独立地表示氢，卤素，氨基，一或二（低级烷基）氨基，低级烷酰基氨基，硝基，氰基，取代或未取代的低级烷基，羟基，低级烷氧基，低级烷硫基，羧基，低级烷氧基羰基，低级烷酰基，芳烷氧基或低级烷酰氧基; R 6，R 7，R 8和R 9独立地表示氢，羟基，取代或未取代的低级烷氧基或芳烷氧基，或者它们中的任何相邻的两个被结合形成亚甲二氧基; R 10表示氢或低级烷基; 并且Y和Z独立地表示作为活性成分的N或C-R11（其中R11表示氢，取代或未取代的低级烷基或卤素）或其药学上可接受的盐。

6. 发明授权

US5302602A Tricyclic thromboxane A.sub.2 antagonists 失效
标题翻译：三环血栓素A2拮抗剂
公开(公告)号：US5302602A
公开(公告)日：1994-04-12
申请号：US884208
申请日：1992-05-18
申请人： Etsuo Oshima , Hiroyuki Obase , Akira Karasawa , Kazuhiro Kubo , Ichiro Miki , Akio Ishii , Hidee Ishii , Kenji Ohmori
发明人： Etsuo Oshima , Hiroyuki Obase , Akira Karasawa , Kazuhiro Kubo , Ichiro Miki , Akio Ishii , Hidee Ishii , Kenji Ohmori
IPC分类号： C07D211/14 , C07D313/12 , C07D333/34 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D471/10 , A61K31/445 , C07D211/22
CPC分类号： C07D405/06 , C07D211/14 , C07D313/12 , C07D333/34 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D471/10
摘要： Novel tricyclic compounds having a TXA.sub.2 antagonizing activity represented by formula (I): ##STR1## possess a potent antagonizing against thromboxane A.sub.2 and also an antiallergic and/or antihistaminic activity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc.
摘要翻译：具有由式（I）表示的TXA2拮抗活性的新型三环化合物：具有对血栓素A2的有效拮抗作用，还具有抗过敏和/或抗组胺活性，并且预期对缺血性疾病具有预防和治疗作用脑血管疾病等

7. 发明授权

US5290782A Xanthine derivatives 失效
标题翻译：黄嘌呤衍生物
公开(公告)号：US5290782A
公开(公告)日：1994-03-01
申请号：US839690
申请日：1992-02-24
申请人： Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka
发明人： Fumio Suzuki , Junichi Shimada , Akio Ishii , Tetsuji Ohno , Akira Karasawa , Kazuhiro Kubo , Hiromi Nonaka
IPC分类号： C07D473/06 , C07D473/08 , C07D473/20 , C07D473/22 , C07D473/02 , A61K31/52
CPC分类号： C07D473/06 , C07D473/08 , C07D473/20 , C07D473/22
摘要： Novel xanthine compounds represented by the following formula: ##STR1## wherein each of X.sup.1 and X.sup.2 independently represents oxygen or sulfur; and Q represents; ##STR2## where ----- represents a single bond or a double bond; Y represents a single bond or alkylene, n represents 0 or 1, each of W.sup.1 and W.sup.2 independently represents hydrogen, lower alkyl or amino, Z represents --CH.sub.2 -, --O--, --S-- or --NH--; represents ##STR3## each of R.sup.1 and R.sup.2 independently represents hydrogen, lower alkyl, allyl or propargyl; and R.sup.3 represents hydrogen or lower alkyl, and when Q represents the groups other than ##STR4## each of R.sup.1, R.sup.2 and R.sup.3 independently represents hydrogen or lower alkyl;provided that when Q is ##STR5## then R.sup.1 R.sup.2 and R.sup.3 are notsimultaneously methyl; and pharmaceutically acceptable salts thereof have a diuretic effect, a renal-protecting effect and a bronchodilatory effect.
摘要翻译：由下式表示的新型黄嘌呤化合物：其中X1和X2各自独立地表示氧或硫; 和Q表示; 其中-----表示单键或双键; Y表示单键或亚烷基，n表示0或1，W1和W2各自独立地表示氢，低级烷基或氨基，Z表示-CH2 - ， - O - ， - S-或-NH-。 R1和R2各自表示氢，低级烷基，烯丙基或炔丙基; 且R 3表示氢或低级烷基，并且当Q表示除R1之外的基团时，R 1，R 2和R 3各自独立地表示氢或低级烷基; 条件是当Q为时，则R1 + L，R2和R3不同时为甲基; 及其药学上可接受的盐具有利尿作用，肾脏保护作用和支气管扩张作用。

8. 发明授权

US5270316A Condensed purine derivatives 失效
标题翻译：凝血嘌呤衍生物
公开(公告)号：US5270316A
公开(公告)日：1993-12-14
申请号：US599758
申请日：1990-10-19
申请人： Fumio Suzuki , Junichi Shimada , Takeshi Kuroda , Kazuhiro Kubo , Akira Karasawa , Tetsuji Ohno , Kenji Ohmori
发明人： Fumio Suzuki , Junichi Shimada , Takeshi Kuroda , Kazuhiro Kubo , Akira Karasawa , Tetsuji Ohno , Kenji Ohmori
IPC分类号： A61K31/00 , A61K31/495 , A61K31/505 , A61K31/519 , A61K31/529 , A61P7/00 , A61P7/10 , A61P9/00 , A61P9/12 , A61P11/00 , A61P11/06 , A61P11/08 , A61P13/00 , A61P13/02 , A61P13/12 , A61P15/00 , C07D471/14 , C07D487/14 , A61K31/52
CPC分类号： C07D471/14 , C07D487/14
摘要： There are disclosed condensed purine derivatives represented by formula; ##STR1## in which R.sup.3 represents hydrogen, lower alkyl or benzyl; each of X.sup.1 and X.sup.2 independently represents hydrogen, lower alkyl, aralkyl or phenyl; and n is an integer of 0 or 1; R.sup.1 represents hydrogen, lower alkyl, alicyclic alkyl, noradamantan-3-yl, dicyclopropylmethyl or styryl; and R.sup.2 represents hydrogen, lower alkyl or alicyclic alkyl; or a pharmaceutically acceptable salt thereof. The derivatives and pharmaceutically acceptable salts are useful as diuretics, renal protecting agents, antiallergic agents and hypotensives.

9. 发明授权

US5143922A Tricyclic thromboxane A.sub.2 antagonists 失效
标题翻译：三环血栓素A2拮抗剂
公开(公告)号：US5143922A
公开(公告)日：1992-09-01
申请号：US616095
申请日：1990-11-20
申请人： Etsuo Oshima , Hiroyuki Obase , Akira Karasawa , Kazuhiro Kubo , Ichiro Miki , Akio Ishii , Hidee Ishii , Kenji Ohmori
发明人： Etsuo Oshima , Hiroyuki Obase , Akira Karasawa , Kazuhiro Kubo , Ichiro Miki , Akio Ishii , Hidee Ishii , Kenji Ohmori
IPC分类号： C07D211/14 , C07D313/12 , C07D333/34 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D471/10
CPC分类号： C07D405/06 , C07D211/14 , C07D313/12 , C07D333/34 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D471/10
摘要： Novel tricyclic compounds having a TXA.sub.2 antagonizing activity represented by formula (I): ##STR1## possess a potent antagonizing action against thromboxane A.sub.2 and also an antiallergic and/or antihistaminic acitvity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc.
摘要翻译：具有由式（I）表示的TXA2拮抗活性的新型三环化合物：对抗凝血恶烷A2具有有效的拮抗作用，并且还具有抗过敏和/或抗组胺活性，并且预期对缺血性具有预防和治疗作用疾病，脑血管疾病等

10. 发明授权

US5010087A Tricyclic compounds and TXA.sub.2 antagonistic compositions thereof 失效
标题翻译：三环化合物和TXA2拮抗组合物
公开(公告)号：US5010087A
公开(公告)日：1991-04-23
申请号：US381330
申请日：1989-07-18
申请人： Etsuo Oshima , Hiroyuki Obase , Akira Karasawa , Kazuhiro Kubo , Ichiro Miki , Akio Ishii
发明人： Etsuo Oshima , Hiroyuki Obase , Akira Karasawa , Kazuhiro Kubo , Ichiro Miki , Akio Ishii
IPC分类号： C07C311/16 , C07C323/44 , C07C323/48 , C07C323/49 , C07D313/12 , C07D337/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D495/04
CPC分类号： C07D405/12 , C07C311/16 , C07C323/44 , C07C323/48 , C07C323/49 , C07D313/12 , C07D337/12 , C07D407/12 , C07D409/12 , C07D495/04 , C07C2103/32
摘要： Novel tricyclic compounds having a TXA.sub.2 -antagonizing activity represented by formula (I): ##STR1## which strongly antagonize an action of thromboxane A.sub.2 and are expected to have preventive and therapeutic effects on ischemica diseases, cerebro-vascular diseases, etc.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式